PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34763937-0	2022	Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.	enzalutamide	18-30	androgen receptor	Homo sapiens	34-51	
34763937-1	2022	OBJECTIVES: We sought to determine the safety and efficacy of the oral androgen receptor antagonist enzalutamide in patients with previously treated, recurrent, AR-positive (AR+) ovarian cancer.	enzalutamide	100-112	androgen receptor	Homo sapiens	71-88